![]() | |
![]() | |
Clinical data | |
---|---|
AHFS/Drugs.com | Consumer Drug Information |
License data | |
Pregnancy category |
|
Routes of administration | Oral |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | Undetermined |
Protein binding | Nearly 100% |
Metabolism | Hepatic, CYP3A4 involved |
Elimination half-life | Variable: 6 to 9 days with normal BMI 16 days if BMI >30 |
Excretion | Fecal (86%) and renal (3%) |
Identifiers | |
| |
CAS Number |
|
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII |
|
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.210.978 |
Chemical and physical data | |
Formula | C22H21Cl3N4O |
Molar mass | 463.79 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Rimonabant (also known as SR141716; trade names Acomplia, Zimulti)[3] is an anorectic antiobesity drug approved in Europe in 2006 but was withdrawn worldwide in 2008 due to serious psychiatric side effects; it was never approved in the United States.[1][2] Rimonabant is an inverse agonist for the cannabinoid receptor CB1 and was first-in-class for clinical development.[4][5]
© MMXXIII Rich X Search. We shall prevail. All rights reserved. Rich X Search